1 – 38 of 38
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Tru-Cut Biopsy in Gynecological Cancer: Adequacy, Accuracy, Safety and Clinical Applicability
(
- Contribution to journal › Article
-
Mark
Age and Referral Route Impact the Access to Diagnosis for Women with Advanced Ovarian Cancer
(
- Contribution to journal › Article
- 2022
-
Mark
Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer
(
- Contribution to journal › Article
-
Mark
The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC)
2022) In Archives of Gynecology and Obstetrics(
- Contribution to journal › Article
-
Mark
Copy number signatures for early diagnosis of high-grade serous ovarian carcinoma
2022) “FUTURE PERSPECTIVES IN OVARIAN CANCER RESEARCH”(
- Contribution to conference › Poster
-
Mark
Ovarian tumor frozen section, a multidisciplinary affair
(
- Contribution to journal › Article
- 2021
-
Mark
Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960–2014 : A population-based cohort study
(
- Contribution to journal › Article
-
Mark
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
(
- Contribution to journal › Article
- 2020
-
Mark
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
(
- Contribution to journal › Article
-
Mark
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer
(
- Contribution to journal › Article
-
Mark
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
(
- Contribution to journal › Article
-
Mark
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
(
- Contribution to journal › Article
- 2019
-
Mark
Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden : a population-based study
(
- Contribution to journal › Article
-
Mark
Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
(
- Contribution to journal › Article
-
Mark
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
(
- Contribution to journal › Article
-
Mark
A targeted mass spectrometry strategy for developing proteomic biomarkers : a case study of epithelial ovarian cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Claudin-4 Expression is Associated with Survival in Ovarian Cancer but Not with Chemotherapy Response
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
(
- Contribution to journal › Article
-
Mark
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
(
- Contribution to journal › Article
- 2017
-
Mark
Claudin-4 expression is associated with progression free survival in ovarian cancer, but not with chemotherapy response
(
- Contribution to journal › Article
-
Mark
Involvement of chromatin remodeling genes and the Rho GTPases RhoB and CDC42 in ovarian clear cell carcinoma
(
- Contribution to journal › Article
- 2016
-
Mark
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
(
- Contribution to journal › Article
- 2015
-
Mark
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.
(
- Contribution to journal › Article
-
Mark
Ovarialcancer är på många sätt en heterogen sjukdom
(
- Contribution to journal › Article
- 2014
-
Mark
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
(
- Contribution to journal › Article
-
Mark
Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
(
- Contribution to journal › Article
-
Mark
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
(
- Contribution to journal › Article
- 2011
-
Mark
Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors
(
- Contribution to journal › Article
- 2010
-
Mark
Genetic profiles distinguish different types of hereditary ovarian cancer.
(
- Contribution to journal › Article
- 2008
-
Mark
Response to letter of Escobar et al.
(
- Contribution to journal › Article
- 2007
-
Mark
Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40.
(
- Contribution to journal › Article
-
Mark
Hereditary Ovarian Cancer mutation frequencies and genetic profiles
2007)(
- Thesis › Doctoral thesis (compilation)
- 2006
-
Mark
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
(
- Contribution to journal › Article
- 2005
-
Mark
Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden
(
- Contribution to journal › Article
- 2004
-
Mark
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations : results of a prospective study in Southern Sweden
(
- Contribution to journal › Article
- 2001
-
Mark
Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report
(
- Contribution to journal › Article
- 2000
-
Mark
BRCA1 and BRCA2 mutations in ovarian cancer : Covariation with specific cytogenetic features
(
- Contribution to journal › Article